Condition
Primary Myelofibrosis (PMF) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Primary Myelofibrosis (PMF) clinical trials that are recruiting, at sites in 24 countries (most in United States (3), Australia (2), Belgium (2)). By phase: Phase 3 (1), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 24Countries
Newest Primary Myelofibrosis (PMF) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Identifying MPN-Specific Immune Targets in Blood and Bone Marrow | — | Brussels, Woluwe | Recruiting | May 15, 2026 |
| PRT12396 for people with high-risk polycythemia vera or myelofibrosis | Phase 1 | Los Angeles, California and 21 other locations | Recruiting | Mar 13, 2026 |
| MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs. | — | Chicago, Illinois and 1 other locations | Recruiting | Jan 23, 2026 |
| Pelabresib plus ruxolitinib for adults with myelofibrosis | Phase 3 | Denver, Colorado and 164 other locations | Recruiting | Jan 22, 2026 |
| Ropeginterferon alfa-2b added to ruxolitinib for people with myelofibrosis | Phase 2 | Hong Kong | Recruiting | Jan 13, 2025 |
All recruiting trials (5)
-
Identifying MPN-Specific Immune Targets in Blood and Bone Marrow
This study tests whether certain T cells in adults with MPN can recognize MPN cells and what antigens those T cells target.
-
PRT12396 for people with high-risk polycythemia vera or myelofibrosis
The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.
-
MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.
Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.
-
Pelabresib plus ruxolitinib for adults with myelofibrosis
This trial will see if adding pelabresib to ruxolitinib helps adults with primary myelofibrosis or post‑PV/post‑ET myelofibrosis who have not previously taken JAK inhibitor therapy.
-
Ropeginterferon alfa-2b added to ruxolitinib for people with myelofibrosis
This will try adding ropeginterferon alfa-2b to ongoing ruxolitinib for adults with myelofibrosis who have had a suboptimal response to ruxolitinib alone.
Related topics
Quick answers
How many Primary Myelofibrosis (PMF) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 24 countries. The most sites are in United States (3 trials), Australia (2 trials), Belgium (2 trials), France (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.